BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 19
• 20
• 21
• 22
• 23
• 25
• 26
• 27
• 28

• Pharm Country

  Pragma Pharmaceuticals, LLC Announces the Launch of Decadron

  Pragma Pharmaceuticals is pleased to announce that it is planning the launch of Decadron (dexamethasone) .5, .75, 4 and 6 mg tablets in early 2018.

  February 16, 2018

   · 

  1 min read
• Pharm Country

  Medicrea Reports Directors’ Dealings Disclosure and Announces Transactions On Securities Of The Company

  In accordance with Article 19 of Regulation (EU) No 596/2014 of April 16th, 2014, the Company has declared to the AMF the acquisition of 60,000 shares on February 13th, 2018 by its Chairman and Chief Executive Officer, Denys Sournac.

  February 16, 2018

   · 

  1 min read
• 

  Policy

  FDA Rejects Apricus Biosciences’ Erectile Dysfunction Cream Vitaros

  The CRL indicates that the FDA cannot approve the NDA for Vitaros in its present form.

  February 16, 2018

   · 

  3 min read
• Policy

  Lipocine Announces Settlement of Securities Class Action Lawsuit

  If a settlement is finally approved by the court, it will resolve all of the claims that were or could have been brought in the action being settled.

  February 16, 2018

   · 

  3 min read
• Loncar Cancer Immunotherapy ETF (CNCR) Surpasses $50 Million in Assets Under Management

  The Loncar Cancer Immunotherapy ETF recently surpassed $50 million in assets under management (AUM), marking a pivotal milestone for the fund.

  February 16, 2018

   · 

  5 min read
• Deals

  Seattle Genetics Announces Expiration of Hart-Scott-Rodino Waiting Period

  Seattle Genetics announced that the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) with respect to Seattle Genetics’ proposed acquisition of Cascadian Therapeutics, Inc. (NASDAQ:CASC) expired at 11:59 p.m. on February 15, 2018.

  February 16, 2018

   · 

  7 min read
• 

  FDA

  AMAG Investors Cheer as Biotech Wins Second Drug Approval This Month

  Makena was approved by the FDA in February 2011 and remains the first and only FDA-approved treatment option currently available for pregnant women who have had a prior spontaneous preterm birth.

  February 16, 2018

   · 

  11 min read
• Myriad Genetics Release: JAMA Oncology Publication Demonstrates EndoPredict (EPClin) Significantly Outperforms Oncotype DX Recurrence Score in Early-Stage Breast Cancer

  A key finding is that Myriad’s EndoPredict significantly outperformed Oncotype DX Recurrence Score at predicting the risk of disease recurrence in patients with early-stage breast cancer.

  February 16, 2018

   · 

  9 min read
• BioMidwest

  Osprey Study Chosen for “Best of Best” Presentation at Society for Cardiovascular Angiography and Interventions Conference

  Osprey Medical Inc. today announced a multi-center observational study for the DyeVert Plus System will feature at the Society for Cardiovascular Angiography and Interventions (SCAI) Scientific Session in April 2018.

  February 16, 2018

   · 

  2 min read
• Biotech Beach

  Two New Studies at the 2018 AAD Annual Meeting Highlight the Clinical Impact and Utilization of the DecisionDx-Melanoma Test for Cutaneous Melanoma

  The data will be presented during the 74th Annual Meeting of the American Academy of Dermatology (AAD), held in San Diego, CA from February 16-18.

  February 16, 2018

   · 

  6 min read